203 related articles for article (PubMed ID: 31401518)
1. Antibody therapy for Lassa fever.
Cross RW; Hastie KM; Mire CE; Robinson JE; Geisbert TW; Branco LM; Ollmann Saphire E; Garry RF
Curr Opin Virol; 2019 Aug; 37():97-104. PubMed ID: 31401518
[TBL] [Abstract][Full Text] [Related]
2. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.
Robinson JE; Hastie KM; Cross RW; Yenni RE; Elliott DH; Rouelle JA; Kannadka CB; Smira AA; Garry CE; Bradley BT; Yu H; Shaffer JG; Boisen ML; Hartnett JN; Zandonatti MA; Rowland MM; Heinrich ML; Martínez-Sobrido L; Cheng B; de la Torre JC; Andersen KG; Goba A; Momoh M; Fullah M; Gbakie M; Kanneh L; Koroma VJ; Fonnie R; Jalloh SC; Kargbo B; Vandi MA; Gbetuwa M; Ikponmwosa O; Asogun DA; Okokhere PO; Follarin OA; Schieffelin JS; Pitts KR; Geisbert JB; Kulakoski PC; Wilson RB; Happi CT; Sabeti PC; Gevao SM; Khan SH; Grant DS; Geisbert TW; Saphire EO; Branco LM; Garry RF
Nat Commun; 2016 May; 7():11544. PubMed ID: 27161536
[TBL] [Abstract][Full Text] [Related]
3. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus.
Cross RW; Fenton KA; Woolsey C; Prasad AN; Borisevich V; Agans KN; Deer DJ; Dobias NS; Fears AC; Heinrich ML; Geisbert JB; Garry RF; Branco LM; Geisbert TW
Cell Rep Med; 2024 Feb; 5(2):101392. PubMed ID: 38280377
[TBL] [Abstract][Full Text] [Related]
5. Identification of Common CD8
Sakabe S; Hartnett JN; Ngo N; Goba A; Momoh M; Sandi JD; Kanneh L; Cubitt B; Garcia SD; Ware BC; Kotliar D; Robles-Sikisaka R; Gangavarapu K; Branco LM; Eromon P; Odia I; Ogbaini-Emovon E; Folarin O; Okogbenin S; Okokhere PO; Happi C; Sabeti PC; Andersen KG; Garry RF; de la Torre JC; Grant DS; Schieffelin JS; Oldstone MBA; Sullivan BM
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269122
[TBL] [Abstract][Full Text] [Related]
6. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.
Heinrich ML; Boisen ML; Nelson DKS; Bush DJ; Cross RW; Koval AP; Hoffmann AR; Beddingfield BJ; Hastie KM; Rowland MM; Aimukanova I; Koval S; Lathigra R; Borisevich V; Momoh M; Sandi JD; Goba A; Odia L; Baimba F; Aiyepada JO; Ebo B; Eromon P; Ugwu C; Folarin O; Olumade T; Onyechi MN; Etafo J; Adeyemi R; Ella EE; Aminu M; Gomerep SS; Eke MA; Ogunsanya O; Akpede GO; Asogun DO; Okogbenin SA; Okokhere PO; Holst J; Shaffer JG; Schieffelin JS; Geisbert TW; Saphire EO; Happi CT; Grant DS; Garry RF; Branco LM
Sci Rep; 2020 Sep; 10(1):16030. PubMed ID: 32994446
[TBL] [Abstract][Full Text] [Related]
7. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation.
Maruyama J; Manning JT; Mateer EJ; Sattler R; Bukreyeva N; Huang C; Paessler S
mSphere; 2019 Sep; 4(5):. PubMed ID: 31554720
[TBL] [Abstract][Full Text] [Related]
8. Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.
Hastie KM; Cross RW; Harkins SS; Zandonatti MA; Koval AP; Heinrich ML; Rowland MM; Robinson JE; Geisbert TW; Garry RF; Branco LM; Saphire EO
Cell; 2019 Aug; 178(4):1004-1015.e14. PubMed ID: 31398326
[TBL] [Abstract][Full Text] [Related]
9. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus.
Cross RW; Heinrich ML; Fenton KA; Borisevich V; Agans KN; Prasad AN; Woolsey C; Deer DJ; Dobias NS; Rowland MM; Lathigra R; Borrega R; Geisbert JB; Garry RF; Branco LM; Geisbert TW
Proc Natl Acad Sci U S A; 2023 Aug; 120(34):e2304876120. PubMed ID: 37590417
[TBL] [Abstract][Full Text] [Related]
10. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.
Mire CE; Cross RW; Geisbert JB; Borisevich V; Agans KN; Deer DJ; Heinrich ML; Rowland MM; Goba A; Momoh M; Boisen ML; Grant DS; Fullah M; Khan SH; Fenton KA; Robinson JE; Branco LM; Garry RF; Geisbert TW
Nat Med; 2017 Oct; 23(10):1146-1149. PubMed ID: 28869611
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.
Cross RW; Mire CE; Branco LM; Geisbert JB; Rowland MM; Heinrich ML; Goba A; Momoh M; Grant DS; Fullah M; Khan SH; Robinson JE; Geisbert TW; Garry RF
Antiviral Res; 2016 Sep; 133():218-222. PubMed ID: 27531367
[TBL] [Abstract][Full Text] [Related]
12. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
Safronetz D; Rosenke K; Westover JB; Martellaro C; Okumura A; Furuta Y; Geisbert J; Saturday G; Komeno T; Geisbert TW; Feldmann H; Gowen BB
Sci Rep; 2015 Oct; 5():14775. PubMed ID: 26456301
[TBL] [Abstract][Full Text] [Related]
13. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates.
Woolsey C; Cross RW; Prasad AN; Agans KN; Borisevich V; Deer DJ; Dobias NS; Fears AC; Harrison MB; Heinrich ML; Fenton KA; Garry RF; Branco LM; Geisbert TW
Emerg Microbes Infect; 2024 Dec; 13(1):2301061. PubMed ID: 38164768
[TBL] [Abstract][Full Text] [Related]
15. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.
Jahrling PB; Peters CJ
Infect Immun; 1984 May; 44(2):528-33. PubMed ID: 6715049
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
[TBL] [Abstract][Full Text] [Related]
17. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin.
Jahrling PB
J Med Virol; 1983; 12(2):93-102. PubMed ID: 6619814
[TBL] [Abstract][Full Text] [Related]
18. Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability.
Gorman J; Cheung CS; Duan Z; Ou L; Wang M; Chen X; Cheng C; Biju A; Sun Y; Wang P; Yang Y; Zhang B; Boyington JC; Bylund T; Charaf S; Chen SJ; Du H; Henry AR; Liu T; Sarfo EK; Schramm CA; Shen CH; Stephens T; Teng IT; Todd JP; Tsybovsky Y; Verardi R; Wang D; Wang S; Wang Z; Zheng CY; Zhou T; Douek DC; Mascola JR; Ho DD; Ho M; Kwong PD
Nat Commun; 2024 Jan; 15(1):285. PubMed ID: 38177144
[TBL] [Abstract][Full Text] [Related]
19. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
[TBL] [Abstract][Full Text] [Related]
20. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization.
Jahrling PB; Frame JD; Rhoderick JB; Monson MH
Trans R Soc Trop Med Hyg; 1985; 79(3):380-4. PubMed ID: 3898484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
